

Supplementary Table 1. The changes in diabetes medication in each subjects during follow-up period

Variable	Subject	Changes in 1 year follow-up (n = 10)	Changes in 5-year follow-up (n = 25)
<i>H. pylori</i> -negative	6		New administration of metformin
	8	Additional metformin and sulfonylurea	Discontinuation of metformin and sulfonylurea
	13		New administration of metformin and sulfonylurea
	15		New administration of mitglinide and insulin
	30	Increased dose of metformin and sulfonylurea	
	32	Additional DPP-4 inhibitor	Discontinuation of DPP-4 inhibitor
	36		Additional metformin
<i>H. pylori</i> -positive non-eradicated	45		New administration of sulfonylurea and DPP-4 inhibitor
	46		Additional DPP-4 inhibitor
	58		New administration of metformin, sulfonylurea and thiazolidinedione
	61	Increased dose of metformin, new administration of α -glucosidase inhibitor	
	63		New administration of metformin
<i>H. pylori</i> -positive eradicated	71	Increased dose of metformin, new administration of sulfonylurea	
	75		Discontinuation of metformin
	76		Increased dose of metformin, new administration of SGLT2 inhibitor
	90		Additional DPP-4 inhibitor
	91	New administration and continuously increased dose of metformin	
	95	New administration of metformin	
			Additional sulfonylurea and α -glucosidase inhibitor
	100		Additional DPP-4 inhibitor
	103	Decreased dose of DPP-4 inhibitor	Discontinuation of DPP-4 inhibitor
	109	Additional sulfonylurea and meglitinide	
	111		New administration of metformin and sulfonylurea
	117		Additional DPP-4 inhibitor
	121		Additional α -glucosidase inhibitor
123	Additional sulfonylurea and α -glucosidase inhibitor	Discontinuation of sulfonylurea and α -glucosidase inhibitor	

DPP-4, dipeptidyl peptidase-4; SGLT2, sodium-glucose cotransporter 2.